Discover
NMRA
Neumora Therapeutics, Inc.
1.62
2 x 1.21
2 x 2.00
bid
ask
-
0.08
4.71%
2 @ 06:00 AM
1.60 -0.02 (1.23%)
| Ytd | -9.50% | |
| 1y | 103.52% |
1.56
day range
1.71
0.77
52 week range
3.65
| Open | 1.71 | Prev Close | 1.70 | Low | 1.56 | High | 1.71 | Mkt Cap | 300.16M |
| Vol | 960.57K | Avg Vol | 2.29M | EPS | -1.33 | P/E | N/A | Forward P/E | -1.01 |
| Beta | N/A | Short Ratio | 4.59 | Inst. Own | 72.13% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 1.85 | 200-d Avg | 2.19 | 1yr Est | 11.77 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-12 | 2024-09 | -0.38 | -0.45 | -0.07 | -18.42% |
| 2024-08-06 | 2024-06 | -0.37 | N/A | N/A | N/A |
| 2024-08-06 | 2024-06 | -0.37 | -0.37 | N/A | N/A |
| 2024-05-07 | 2024-03 | -0.35 | N/A | N/A | N/A |
| 2024-05-07 | 2024-03 | -0.35 | -0.34 | 0.01 | 2.86% |
| 2024-03-07 | 2023-12 | -0.65 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2025-02-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2025-01-06 | B of A Securities | Upgrade | Buy | Buy |
| 2025-01-03 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2025-01-02 | Needham | Upgrade | Buy | Buy |
| 2024-12-16 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-22 | RBC Capital | Upgrade | Outperform | Outperform |
Profile
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-02-17 | AURORA DALJIT SINGH | Officer | 203.64K | Sale |
| 2025-02-17 | BERNS PAUL L | Chief Executive Officer | 7.80M | Sale |
| 2024-06-12 | BUROW KRISTINA M | Director and Beneficial Owner of more than 10% of a Class of Security | 31.98M | Stock Award(Grant) |
| 2024-10-17 | FUST MATTHEW K. | Director | 20.10K | Conversion of Exercise of derivative security |
| 2024-06-12 | HALAWA ALAA A. | Director | 20.10K | Stock Award(Grant) |
| 2024-06-12 | HO MAYKIN | Director | 20.10K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-12-30 | FMR, LLC | 7.84M | 12.23M | 4.85% |
| 2024-12-30 | Blackrock Inc. | 7.11M | 11.09M | 4.40% |
| 2024-12-30 | Softbank Group Corporation | 6.54M | 10.20M | 4.05% |
| 2024-12-30 | T. Rowe Price Investment Management, Inc. | 5.00M | 7.80M | 3.10% |
| 2024-12-30 | Vanguard Group Inc | 4.57M | 7.13M | 2.83% |
| 2024-12-30 | MIC Capital Management UK LLP | 4.46M | 6.96M | 2.76% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 2.39M | 3.73M | 1.48% |
| 2024-12-30 | iShares Russell 2000 ETF | 2.27M | 3.54M | 1.41% |
| 2024-12-30 | Price (T.Rowe) Small-Cap Value Fund | 1.30M | 2.02M | 0.80% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 1.25M | 1.95M | 0.77% |
| 2024-12-30 | Price (T.Rowe) Small Cap Stock Fund | 965.14K | 1.51M | 0.60% |
| 2024-10-30 | Fidelity Small Cap Index Fund | 860.15K | 1.34M | 0.53% |